Evolus Inc EOLS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:16 PM EDT
13.09quote price arrow down-0.30 (-2.24%)
Volume
27,185
Close
13.39quote price arrow up+0.09 (+0.68%)
Volume
429,102
52 week range
7.07 - 15.43
Loading...
  • Open13.31
  • Day High13.63
  • Day Low13.24
  • Prev Close13.30
  • 52 Week High15.43
  • 52 Week High Date03/04/24
  • 52 Week Low7.07
  • 52 Week Low Date07/06/23

Key Stats

  • Market Cap821.806M
  • Shares Out61.37M
  • 10 Day Average Volume0.65M
  • Dividend-
  • Dividend Yield-
  • Beta1.32
  • YTD % Change27.16

KEY STATS

  • Open13.31
  • Day High13.63
  • Day Low13.24
  • Prev Close13.30
  • 52 Week High15.43
  • 52 Week High Date03/04/24
  • 52 Week Low7.07
  • 52 Week Low Date07/06/23
  • Market Cap821.806M
  • Shares Out61.37M
  • 10 Day Average Volume0.65M
  • Dividend-
  • Dividend Yield-
  • Beta1.32
  • YTD % Change27.16

RATIOS/PROFITABILITY

  • EPS (TTM)-1.08
  • P/E (TTM)-12.35
  • Fwd P/E (NTM)-46.98
  • EBITDA (TTM)-39.843M
  • ROE (TTM)-1,279.29%
  • Revenue (TTM)202.085M
  • Gross Margin (TTM)69.54%
  • Net Margin (TTM)-30.52%
  • Debt To Equity (MRQ)-581.75%

EVENTS

  • Earnings Date05/07/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Evolus Inc

 

Profile

MORE
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin...
Vikram Malik
Non-Executive Chairman of the Board, Independent Director
David Moatazedi
President, Chief Executive Officer, Director
Sandra Beaver
Chief Financial Officer
Nareg Sagherian
Vice President, Head of Global Investor Relations and Corporate Communications
Address
520 Newport Center Dr Ste 1200
Newport Beach, CA
92660-7022
United States

Top Peers

SYMBOLLASTCHG%CHG
PACB
Pacific Biosciences of California Inc
1.99+0.16+8.74%
ADPT
Adaptive Biotechnologies Corp
3.22+0.21+6.98%
AKBA
Akebia Therapeutics Inc
1.49+0.12+8.76%
MNKD
MannKind Corp
4.40+0.01+0.23%
RVNC
Revance Therapeutics Inc
4.10+0.15+3.80%